Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
暂无分享,去创建一个
Linda Mol | Miriam Koopman | O. Dalesio | C. Punt | M. Koopman | G. Vreugdenhil | F. Erdkamp | G. Creemers | M. Tesselaar | P. Slee | N. Antonini | Otilia Dalesio | Gerard Vreugdenhil | Cees J Rodenburg | Ninja F Antonini | J. Douma | Cornelis JA Punt | Joep Douma | Jaap Wals | Aafke H Honkoop | Frans LG Erdkamp | Robert S de Jong | Olaf JL Loosveld | Aart van Bochove | Harm AM Sinnige | Geert-Jan M Creemers | Margot ET Tesselaar | Peter H Th J Slee | Marjon JBP Werter | C. Rodenburg | L. Mol | O. Loosveld | A. Honkoop | J. Wals | M. Werter | A. Bochove | R. S. Jong | Harm A. M. Sinnige
[1] R. Herrmann,et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[3] M. Valerio,et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[5] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Rea,et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Punt,et al. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] E. Van Cutsem,et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Erlichman. Fluorouracil and leucovorin for metastatic colorectal cancer. , 1990, Journal of chemotherapy.
[12] C. Punt. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] E Harrison,et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Fuchs,et al. A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Van Cutsem,et al. Tolerability of fluoropyrimidines appears to differ by region. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Koopman,et al. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] E. Van Cutsem,et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Mariani,et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma , 2004, Cancer.
[19] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[20] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[21] J. Berlin,et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Stupp,et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[24] Richard J Stephens,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.
[25] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.